Compare TEAM & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TEAM | IQV |
|---|---|---|
| Founded | 2002 | 1982 |
| Country | Australia | United States |
| Employees | N/A | 93000 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.3B | 41.3B |
| IPO Year | 2015 | 2013 |
| Metric | TEAM | IQV |
|---|---|---|
| Price | $78.04 | $173.04 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 24 | 16 |
| Target Price | $206.42 | ★ $232.56 |
| AVG Volume (30 Days) | ★ 7.1M | 2.8M |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.52 | 4.67 |
| EPS | N/A | ★ 7.84 |
| Revenue | $5,215,304,000.00 | ★ $9,739,000,000.00 |
| Revenue This Year | $24.63 | $6.76 |
| Revenue Next Year | $17.66 | $5.85 |
| P/E Ratio | ★ N/A | $22.34 |
| Revenue Growth | 19.66 | ★ 41.60 |
| 52 Week Low | $67.85 | $134.65 |
| 52 Week High | $242.00 | $247.05 |
| Indicator | TEAM | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 36.84 | 40.80 |
| Support Level | $67.85 | $156.43 |
| Resistance Level | $177.94 | $193.26 |
| Average True Range (ATR) | 4.72 | 6.62 |
| MACD | 2.70 | 2.92 |
| Stochastic Oscillator | 59.53 | 59.11 |
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.